Global Recombinant Vaccines Market Analysis For 2026–2030 With Strategic Insights

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Recombinant Vaccines Market From 2026 To 2030?

The recombinant vaccines market size has experienced swift expansion in recent years. It is projected to increase from $15.79 billion in 2025 to $17.69 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.0%. The growth observed in previous periods is largely due to the effectiveness of hepatitis B recombinant vaccines, established global vaccination programs, a rise in awareness concerning viral diseases, increased funding for immunization, and regulatory encouragement for safer vaccine platforms.

The recombinant vaccines market size is projected to undergo significant expansion in the upcoming years. It is forecast to reach $28.07 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.2%. This growth over the forecast period is primarily due to the increasing demand for precision vaccines, the expansion of vaccines for emerging diseases, a rise in adult booster programs, growing global immunization coverage, and a strong pipeline of recombinant candidates. Noteworthy trends during this period include an increase in recombinant subunit vaccines, the broadening of vector-based vaccine platforms, a rise in adult immunization initiatives, the growth of combination recombinant vaccines, and an enhanced focus on long-duration immunity.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33287&type=smp

Which Drivers Are Supporting The Recombinant Vaccines Market Growth?

The escalating occurrence of infectious diseases is anticipated to drive the recombinant vaccines market’s growth in the foreseeable future. An infectious disease is defined as an illness caused by various germs, including bacteria, viruses, fungi, or parasites, capable of spreading between individuals either directly or indirectly. The rise in infectious disease prevalence is attributed to poor sanitation and hygiene, where insufficient access to clean water, proper sanitation facilities, and effective waste management enables the facile transmission of harmful microorganisms through contaminated food, water, and personal interactions, thereby elevating the risk of infections. Recombinant vaccines work by utilizing biologically engineered genetic material derived from pathogens to elicit an immune response, thus preventing infectious diseases without inducing illness. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based national agency, the most frequently reported sexually transmitted infections in Australia in 2023 included over 109,000 notifications of chlamydia and more than 40,000 of gonorrhea, along with over 6,400 cases of infectious syphilis, underscoring the augmented incidence and ongoing public health challenges. Thus, the increasing prevalence of infectious diseases is a key factor propelling the expansion of the recombinant vaccines market.

How Is The Recombinant Vaccines Market Broken Down By Segment Categories?

The recombinant vaccines market covered in this report is segmented –

1) By Type: Subunit Vaccines; Vector-Based Vaccines

2) By Disease Indication: Human Papillomavirus (HPV); Herpes Zoster; Hepatitis B; Other Diseases

3) By Route Of Administration: Parenteral; Other Route Of Administrations

4) By End User: Pediatric; Adults

Subsegments:

1) By Subunit Vaccines: Protein Subunit Vaccines; Polysaccharide Subunit Vaccines; Conjugate Subunit Vaccines; Glycopeptide Subunit Vaccines; Recombinant Subunit Vaccines

2) By Vector-Based Vaccines: Viral Vector Vaccines; Non Viral Vector Vaccines; Replicating Vector Vaccines; Non Replicating Vector Vaccines; Bacterial Vector Vaccines

Which Trends Are Expected To Impact The Recombinant Vaccines Market?

Major companies operating in the recombinant vaccines market are prioritizing the development of novel vaccines, exemplified by the recombinant 9-valent HPV vaccine, to gain a competitive edge. The recombinant 9-valent HPV vaccine is designed to protect against nine types of human papillomavirus (HPV) and is produced using recombinant DNA technology, meaning it is created in a laboratory setting without live virus and assists in preventing HPV-related diseases such as cervical cancer and genital warts. For instance, in August 2023, Jiangsu Recbio Technology Co. Ltd., a China-based biopharmaceutical company, advanced REC603, its recombinant 9-valent HPV vaccine, through Phase III clinical follow-up, with 24-month observations continuing. The vaccine demonstrated strong immunogenicity, a favorable safety profile, scalable manufacturing potential, and long-term efficacy, thereby supporting its potential for broad HPV prevention and commercialization.

Which Players Are Present In The Recombinant Vaccines Market Space?

Major companies operating in the recombinant vaccines market are Johnson And Johnson, Merck And Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc., Serum Institute Of India Private Limited, Vaxcyte Inc., Bharat Biotech International Limited, and Transgene S A.

Get The Full Recombinant Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/recombinant-vaccines-market-report

Where Is The Recombinant Vaccines Market Primarily Concentrated By Region?

North America was the largest region in the recombinant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Recombinant Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33287&type=smp

Browse Through More Reports Similar to the Global Recombinant Vaccines Market 2026, By The Business Research Company

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Ruminant Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/ruminant-vaccines-global-market-report

Vaccine Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795